We are international
Donate
TEXT SIZE   
   back

The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®

- Black Swan Research Initiative (BSRI®) Goal is Improving Treatment Options for Myeloma Patients 

- Onyx Partnership to Support Significant Research Initiative

12.06.13

North Hollywood, CA and South San Francisco, CA, December 6, 2013 -- The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure – and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced the start of a multi-year collaboration in support of the IMF’s Black Swan Research Initiative® (BSRI®). The BSRI is led by a multinational consortium of leading myeloma experts who are studying and harnessing new technologies and treatments with the goal of developing a cure for myeloma. 

“The goal of bridging the gap from long-term remission to cure is in sight,” said Brian G.M. Durie, M.D., Chairman and Co-founder of the IMF. “With recent technological advances, a group of elite researchers working together, and support from partners like Onyx, BSRI aims to find a cure for myeloma by identifying the best treatments to use at the best time to achieve the best possible outcome for each patient. To achieve the program’s objective, BRSI plans to define and assess minimal residual disease (MRD), or MRD-Zero™ as a clinical endpoint.

BSRI researchers are developing sophisticated and extremely sensitive tests to measure MRD at the cellular and molecular levels in myeloma patients. This would precisely measure myeloma levels in the body and patients’ response to therapy. The MRD testing will be standardized and validated so clinicians around the globe would be able to use the same approach. Onyx, the inaugural industry sponsor of BSRI, will partner closely with the IMF to support this BSRI initiative.

“We are proud to work in partnership with the IMF to better understand myeloma at a molecular level in order to help identify the best treatments for individual patients,” said Homa Yeganegi, Vice President of Medical and Scientific Affairs at Onyx. “We share the IMF’s commitment to improving the lives of patients while working toward a cure, and we look forward to the outputs from this important research initiative that will ultimately impact the way myeloma patients are treated.”

“It is an incredibly exciting time for myeloma patients and researchers,” said Susie Novis, President and Co-founder of the IMF. “As new treatment options are improving outcomes and quality of life for patients, the BSRI team is committed to now move forward to the next stage in advancing science, with the ultimate goal of curing patients. We are grateful for Onyx’s belief in BSRI and their commitment to myeloma patients.”

Until recently, myeloma research focused on comparing one treatment to another to help patients achieve comparatively better progression-free survival or overall survival. Currently, it takes between 10 to 15 years to develop, test and get a new drug approved1. The testing developed under the BSRI is expected to determine the efficacy of new drugs in months rather than years, thus, potentially speeding global approval of new drugs and lowering the cost of bringing a drug to market. 

Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that affects production of red cells, white cells and stem cells and can damage bone. It is the second most common blood cancer.

To learn more about the Black Swan Research Initiative, please visit: www.blackswan.myeloma.org.
 

ABOUT THE INTERNATIONAL MYELOMA FOUNDATION 
Celebrating its 23rd anniversary, the International Myeloma Foundation reaches more than 240,000 members in 120 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses on four key areas: research, education, support, and advocacy. To date, the IMF has conducted more than 250 educational seminars worldwide, maintains a world-renowned hotline, and established the International Myeloma Working Group (IMWG), a collaborative research initiative focused on improving myeloma treatment options for patients. The IMF can be reached at (800) 452-CURE (2873). The global website is www.myeloma.org. Follow the IMF on Twitter @IMFmyeloma.  

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com. Onyx Pharmaceuticals is on Twitter. Sign up to follow our Twitter feed @OnyxPharm at http://twitter.com/OnyxPharm.  

1 “PhRMA Profile 2013” PhRMA. Available at http://phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf. Accessed November 25, 2013.

CONTACTS: 

IMF
Debra Gendel
310-710-1903
debra.gendel@initiatePR.com

Onyx Pharmaceuticals, Inc.
Danielle Bertrand (media)
1-650-266-2114


 related videos
 related articles
#AskDrDurie: My Mai...
#AskDrDurie: Can Mye...
10 PASSI PER CURA MI...
10 Steps to Better C...
10 Steps to Happy Ho...
2011 IMF Holiday Gif...
New Study: The Searc...
Comprender El Tratam...
...
ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Oc...
Advocacy Update - Se...
Advocacy Update: The...
As the Bill Turns......
ASCO 2012: Dr. Pasho...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Pande...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Weise...
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken An...
Audio Recording of C...
August 2013 Advocate...
Breaking News: Pomal...
FDA Recognition of E...
Freelite and Hevylit...
Health Reform and Yo...
Highlights from the ...
IMF 6th Annual Comed...
IMF Board Member Edi...
IMF Nurse Leadership...
IMF Responds to Prop...
IMWG 2014 Conference...
It is Officially Mye...
jc test
Live from ASH 2012: ...
Live! The Boca Raton...
Living Well with Mye...
Living Well With Mye...
Myelom Merkur - Früh...
MYELOMA AWARENESS MO...
Myeloma Canada Annou...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Febr...
Myeloma Minute Janu...
Myeloma Minute July...
Myeloma Minute June...
Myeloma Minute Marc...
Myeloma Minute May ...
Myeloma Minute Nove...
Myeloma Minute Octo...
Myeloma Minute Octo...
Myeloma Minute Sept...
Myeloma MinuteJune 1...
Myeloma MinuteMay 24...
Myeloma Today Spring...
New! Free Teleconfer...
Patienten Handbuch
Pomalidomide + carfi...
Should Myeloma Patie...
Special Myeloma Minu...
STEP 7: CONSOLIDATIO...
STEP 8: KEEPING TRAC...
Stillwater, Minn., M...
Teleconference: Myel...
The Emerging Role of...
The Hope Society
THE IMF AT ASH 2012
The IMF Gains Nation...
The IMF Spearheads N...
The Importance of Cl...
The IMWG Conference ...
The International My...
The International My...
View the IMF’s Multi...
Webcast from the 201...
Клиническое значение...

ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
#AskDrDurie: My Maintenance was Stopped Because the Side Effects were Too Bad. How Common is That?
#AskDrDurie: Can Myeloma Run In The Family?
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care®
10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique

New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage

Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre



Third in the popular series of debates that debuted in Amsterdam in 2012.

Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific

ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - October 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken Anderson's Overview
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
August 2013 Advocate of the Month: Judy Lewis
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Freelite and Hevylite will help the Black Swan Research Initiative find the best treatment to cure multiple myeloma
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
Highlights from the 5th Annual IMWG Summit: Part 2
IMF 6th Annual Comedy Celebration
benefiting the Peter Boyle Research Fund
October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
IMWG 2014 Conference Series Debate: Making Sense of Treatment
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Living Well With Myeloma:
Understanding the Immune System and Lab Values in Myeloma
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 24, 2013
Myeloma Minute
October 25, 2012
Myeloma Minute
September 18, 2014
Myeloma Minute
June 13, 2013
Myeloma Minute
May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
Patienten Handbuch
Pomalidomide + carfilzomib trial recruiting patients.
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Gains National Recognition for Myeloma Awareness Month in 2014
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
The IMWG Conference Series "Making Sense of Treatment"
June 11, 2014
The International Myeloma Foundation Reports Live from the 2013 ASH Meeting in New Orleans
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
View the IMF’s Multiple Myeloma Journalists’ Workshop and Webcast from ASH 2013 in New Orleans
Webcast from the 2014 Boca Raton Patient & Family Seminar
February 28 - March 1, 2014

Клиническое значение электрофореза белковых фракций